Angiographically-assessed coronary artery disease associates with HDL particle size in women

Atherosclerosis

Volumn 223, Issue 2, 2012, Pages 359-364

  Blackburn, Patricia ^a,b   Lemieux, Isabelle ^a   Lamarche, Benoît ^c,d   Bergeron, Jean ^e   Perron, Patrice ^f   Tremblay, Gérald ^f   Gaudet, Daniel ^f   Després, Jean Pierre ^a,c  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ DU QUÉBEC À CHICOUTIMI   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d LAVAL UNIVERSITY   (Canada)

^e Université Laval   (Canada)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Coronary artery disease; HDL particle size; Lipoproteins and lipids; Women

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; AGED; ANGIOGRAPHY; ARTICLE; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PARTICLE SIZE; PHENOTYPE; PRIORITY JOURNAL; RISK; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; ELECTROPHORESIS; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS, HDL; LOGISTIC MODELS; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY, ABDOMINAL; ODDS RATIO; PARTICLE SIZE; PHENOTYPE; PREDICTIVE VALUE OF TESTS; QUEBEC; RISK ASSESSMENT; RISK FACTORS; WAIST CIRCUMFERENCE;

EID: 84864750902     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.05.016     Document Type: Article

References (38)

1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
2. Ballantyne C., Arroll B., Shepherd J. Lipids and CVD management: towards a global consensus. Eur Heart J 2005, 26:2224-2231.
3. Hill S.A., McQueen M.J. Reverse cholesterol transport-a review of the process and its clinical implications. Clin Biochem 1997, 30:517-525.
4. Sviridov D., Nestel P. Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis 2002, 161:245-254.
5. von Eckardstein A., Huang Y., Assmann G. Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr Opin Lipidol 1994, 5:404-416.
6. Pascot A., Lemieux I., Prud'homme D., et al. Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. J Lipid Res 2001, 42:2007-2014.
7. Otvos J.D., Collins D., Freedman D.S., et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006, 113:1556-1563.
8. Tilly-Kiesi M., Lichtenstein A.H., Joven J., et al. Impact of gender on the metabolism of apolipoprotein A-I in HDL subclasses LpAI and LpAI: AII in older subjects. Arterioscler Thromb Vasc Biol 1997, 17:3513-3518.
9. Cheung M.C., Brown B.G., Wolf A.C., Albers J.J. Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease. J Lipid Res 1991, 32:383-394.
10. Williams P.T., Superko H.R., Haskell W.L., Alderman E.L., Blanche P.J., Holl L.G., Krauss R.M. Smallest LDL particles are most strongly related to coronary disease progression in men. Arterioscler Thromb Vasc Biol 2003, 23:314-321.
11. Freedman D.S., Otvos J.D., Jeyarajah E.J., Barboriak J.J., Anderson A.J., Walker J.A. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol 1998, 18:1046-1053.
12. Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
13. Lemieux I., Pascot A., Couillard C., et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?. Circulation 2000, 102:179-184.
14. Arsenault B.J., Lemieux I., Després J.P., Wareham N.J., Kastelein J.J., Khaw K.T., Boekholdt S.M. The hypertriglyceridemic-waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk prospective population study. CMAJ 2010, 182:1427-1432.
15. Vohl M.C., Moorjani S., Roy M., et al. Geographic distribution of French-Canadian low-density lipoprotein receptor gene mutations in the Province of Quebec. Clin Genet 1997, 52:1-6.
16. Lohman T.G., Roche A.F., Martorell R. Anthropometric standardization reference manuel 1988, Human Kinetics Books, Champaign, IL.
17. Burstein M., Samaille J. Sur un dosage rapide du cholestérol lié aux beta-lipoprotéines du sérum. Clin Chim Acta 1960, 5:609-610.
18. Warnick G.R., Benderson J., Albers J.J. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high- density-lipoprotein cholesterol. Clin Chem 1982, 28:1379-1388.
19. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
20. Moorjani S., Dupont A., Labrie F., et al. Increase in plasma high density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism 1987, 36:244-250.
21. Richterich R., Dauwalder H. Determination of plasma glucose by hexokinase-glucose-6-phosphate dehydrogenase method. Schweiz Med Wochenschr 1971, 101:615-618.
22. Desbuquois B., Aurbach G.D. Use of polyethylene glycol to separate free and antibody- bound peptide hormones in radioimmunoassays. J Clin Endocrinol Metab 1971, 37:732-738.
23. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
24. Gaudet D., Vohl M.C., Perron P., et al. Relationships of abdominal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL receptor gene. Circulation 1998, 97:871-877.
25. Pérusse M., Pascot A., Després J.P., Couillard C., Lamarche B. A new method for HDL particle sizing by polyacrylamide gradient gel electrophoresis using whole plasma. J Lipid Res 2001, 42:1331-1334.
26. Lamon-Fava S., Herrington D.M., Reboussin D.M., et al. Plasma levels of HDL subpopulations and remnant lipoproteins predict the extent of angiographically-defined coronary artery disease in postmenopausal women. Arterioscler Thromb Vasc Biol 2008, 28:575-579.
27. Garvey W.T., Kwon S., Zheng D., et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003, 52:453-462.
28. Ruotolo G., Ericsson C.G., Tettamanti C., et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 1998, 32:1648-1656.
29. Arsenault B.J., Lemieux I., Després J.P., et al. HDL particle size and the risk of coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Atherosclerosis 2009, 206:276-281.
30. Stampfer M.J., Krauss R.M., Ma J., Blanche P.J., Holl L.G., Sacks F.M., Hennekens C.H. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996, 276:882-888.
31. Lamarche B., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J., Després J.P. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 1997, 17:1098-1105.
32. Xu Y., Fu M. Alterations of HDL subclasses in hyperlipidemia. Clin Chim Acta 2003, 332:95-102.
33. Yang Y., Yan B., Fu M., Xu Y., Tian Y. Relationship between plasma lipid concentrations and HDL subclasses. Clin Chim Acta 2005, 354:49-58.
34. Lemieux I., Poirier P., Bergeron J., et al. Hypertriglyceridemic waist: a useful screening phenotype in preventive cardiology?. Can J Cardiol 2007, 23(Suppl B):23B-31B.
35. Soderlund S., Watanabe H., Ehnholm C., Jauhiainen M., Taskinen M.R. Increased apolipoprotein E level and reduced high-density lipoprotein mean particle size associate with low high-density lipoprotein cholesterol and features of metabolic syndrome. Metabolism 2010, 59:1502-1509.
36. Lee M., Jang Y., Kim K., Cho H., Jee S.H., Park Y., Kim M.K. Relationship between HDL3 subclasses and waist circumferences on the prevalence of metabolic syndrome: KMSRI-Seoul Study. Atherosclerosis 2010, 213:288-293.
37. Nissen S.E., Yock P. Intravascular ultrasound: novel pathophysiological insights and current clinical applications. Circulation 2001, 103:604-616.
38. Mackey R.H., Kuller L.H., Sutton-Tyrrell K., Evans R.W., Holubkov R., Matthews K.A. Hormone therapy, lipoprotein subclasses, and coronary calcification: the Healthy Women Study. Arch Intern Med 2005, 165:510-515.